Tumor Biology

, Volume 36, Issue 7, pp 5699–5706 | Cite as

Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo

  • Jianli Zhang
  • Yue Hong
  • Jie Shen
Research Article


Lung cancer is a global health problem. The search for new therapeutic approaches for the treatment of lung cancer is important. Here, we reported that the AKT inhibitor perifosine and the MEK\ERK inhibitor MEK-162 synergistically induced lung cancer cell (A549 and H460 lines) growth inhibition and apoptosis. The combined efficiency was significantly higher than either agent alone. For the molecular study, perifosine and MEK-162 worked together to concurrently block AKT, mammalian target of rapamycin (mTOR) complex 1 (mTORC1), and MEK-ERK signalings in lung cancer cells, while either agent alone only affected one or two signalings with lower efficiency. In vivo, MEK-162 and perifosine co-administration dramatically inhibited A549 lung cancer xenograft growth, without inducing apparent toxicities. The synergistic activity in vivo was again superior than either agent alone. Thus, perifosine and MEK-162 combination is biologically plausible by acting through effects on different proliferation and survival-related signaling pathways. Our in vitro and in vivo results support the feasibility of investigating the synergism regimen in clinical tests.


Lung cancer Perifosine MEK-162 PI3K-AKT-mTOR MEK-ERK Synergism 



Enzyme-linked immunosorbent assay


Extracellular regulated kinase


Fetal bovine serum


Mammalian target of rapamycin


Mammalian target of rapamycin (mTOR) complex 1


Non-small cell lung cancers




Polyvinylidene fluoride


Renal cell carcinoma



This work is supported by the National Science Foundation of China.

Conflicts of interest



  1. 1.
    Raez LE, Lilenbaum R. Chemotherapy for advanced non-small-cell lung cancer. Clin Adv Hematol Oncol. 2004;2:173–8.PubMedGoogle Scholar
  2. 2.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.CrossRefPubMedGoogle Scholar
  3. 3.
    Langer C, Lilenbaum R. Role of chemotherapy in patients with poor performance status and advanced non-small cell lung cancer. Semin Oncol. 2004;31:8–15.CrossRefPubMedGoogle Scholar
  4. 4.
    Papadimitrakopoulou V. Development of pi3k/akt/mtor pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol. 2012;7:1315–26.CrossRefPubMedGoogle Scholar
  5. 5.
    Vanhaesebroeck B, Stephens L, Hawkins P. Pi3k signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012;13:195–203.CrossRefPubMedGoogle Scholar
  6. 6.
    Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8:627–44.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Fruman DA, Rommel C. Pi3k and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014;13:140–56.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase b activation. Mol Cancer Ther. 2003;2:1093–103.PubMedGoogle Scholar
  9. 9.
    Gills JJ, Dennis PA. Perifosine: update on a novel akt inhibitor. Curr Oncol Rep. 2009;11:102–10.CrossRefPubMedGoogle Scholar
  10. 10.
    Fensterle J, Aicher B, Seipelt I, Teifel M, Engel J. Current view on the mechanism of action of perifosine in cancer. Anti Cancer Agents Med Chem. 2014;14:629–35.CrossRefGoogle Scholar
  11. 11.
    Qin LS, Yu ZQ, Zhang SM, Sun G, Zhu J, Xu J, et al. The short chain cell-permeable ceramide (c6) restores cell apoptosis and perifosine sensitivity in cultured glioblastoma cells. Mol Biol Rep. 2013;40:5645–55.CrossRefPubMedGoogle Scholar
  12. 12.
    Chen MB, Wu XY, Tao GQ, Liu CY, Chen J, Wang LQ, et al. Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro. Int J Cancer. 2012;131:2487–98.CrossRefPubMedGoogle Scholar
  13. 13.
    Pitter KL, Galban CJ, Galban S, Tehrani OS, Li F, Charles N, et al. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One. 2011;6:e14545.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Fei HR, Chen G, Wang JM, Wang FZ. Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of akt phosphorylation. Cytotechnology. 2010;62:449–60.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther. 2010;9:963–75.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kusters-Vandevelde HV, Willemsen AE, Groenen PJ, Kusters B, Lammens M, Wesseling P, et al. Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor. Acta Neuropathol Commun. 2014;2:41.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A non-randomised, open-label phase 2 study. Lancet Oncol. 2013;14:249–56.CrossRefPubMedGoogle Scholar
  18. 18.
    Thumar J, Shahbazian D, Aziz SA, Jilaveanu LB, Kluger HM. MEK targeting in N-RAS mutated metastatic melanoma. Mol Cancer. 2014;13:45.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6:27.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Tong Y, Huang H, Pan H. Inhibition of MEK/ERK activation attenuates autophagy and potentiates pemetrexed-induced activity against HepG2 hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2015;456:86–91.CrossRefPubMedGoogle Scholar
  21. 21.
    Zhang JL, Xu Y, Shen J. Cordycepin inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-alpha production via activating amp-activated protein kinase (AMPK) signaling. Int J Mol Sci. 2014;15:12119–34.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Shen J, Liang L, Wang C. Perifosine inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-alpha production via regulation multiple signaling pathways: New implication for Kawasaki disease (KD) treatment. Biochem Biophys Res Commun. 2013;437:250–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Fu L, Kim YA, Wang X, Wu X, Yue P, Lonial S, et al. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res. 2009;69:8967–76.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Ji C, Yang YL, Yang Z, Tu Y, Cheng L, Chen B, et al. Perifosine sensitizes UVB-induced apoptosis in skin cells: new implication of skin cancer prevention? Cell Signal. 2012;24:1781–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Dasmahapatra GP, Didolkar P, Alley MC, Ghosh S, Sausville EA, Roy KK. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin Cancer Res. 2004;10:5242–52.CrossRefPubMedGoogle Scholar
  26. 26.
    Li X, Luwor R, Lu Y, Liang K, Fan Z. Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene. 2006;25:525–35.PubMedGoogle Scholar
  27. 27.
    Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C, et al. Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. Prostate. 2008;68:965–74.CrossRefPubMedGoogle Scholar
  28. 28.
    Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 2014;13:1021–31.CrossRefPubMedGoogle Scholar
  29. 29.
    Zaytseva YY, Valentino JD, Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Lett. 2012;319:1–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9–22.CrossRefPubMedGoogle Scholar
  31. 31.
    Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6:729–34.CrossRefPubMedGoogle Scholar
  32. 32.
    Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell. 2005;121:179–93.CrossRefPubMedGoogle Scholar
  33. 33.
    Ma L, Teruya-Feldstein J, Bonner P, Bernardi R, Franz DN, Witte D, et al. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res. 2007;67:7106–12.CrossRefPubMedGoogle Scholar
  34. 34.
    Sun H, Yu T, Li J. Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition. Cancer Lett. 2011;310:118–28.CrossRefPubMedGoogle Scholar
  35. 35.
    Yao C, Wei JJ, Wang ZY, Ding HM, Li D, Yan SC, et al. Perifosine induces cell apoptosis in human osteosarcoma cells: new implication for osteosarcoma therapy? Cell Biochem Biophys. 2013;65:217–27.CrossRefPubMedGoogle Scholar
  36. 36.
    Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res. 2005;65:2422–32.CrossRefPubMedGoogle Scholar
  37. 37.
    Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd JW, et al. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science. 2002;298:846–50.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Respiratory DiseasesThe First Affiliated Hospital of Zhejiang UniversityHangzhouChina
  2. 2.Department of Pediatricsthe First Affiliated Hospital of Zhejiang UniversityHangzhouChina

Personalised recommendations